Company: IMNN
Filing Date: 2025-06-09
Form Type: 8-K
Source: 0001641172-25-014279
Chunk: 1

Company: Imunon, Inc.
Filing Date: 2025-06-09
Form: 8-K
Item: Item 8.01
Chunk 1
---
daq at least until the Panel
renders a decision following the hearing.

As
a separate matter, the Company recently completed a transaction below that had a positive impact on the Company’s stockholders’
equity. On May 30, 2025 and June 2, 2025, warrant holders exercised warrants previously issued in a registered direct/private placement
offering that closed on August 1, 2024, resulting in aggregate net proceeds to the Company of $2.0 million. The Company’s stockholders’
equity as of May 31, 2025, taking into effect the recent warrant exercises, is $3.0 million.

Except
for the factual statements made herein, information contained in this report consists of forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that are difficult to predict,
including statements regarding the Company’s ability to regain compliance with Nasdaq’s continued listing requirements. Words
such as “will,” “believes,” “intends,” “expects,” “plans,” and similar expressions,
or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking.
Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained
in such statements, including, without limitation, risks related to the Company’s ability to regain compliance with Nasdaq’s
continued listing requirements or otherwise maintain compliance with any other listing requirement of The Nasdaq Capital Market, the
potential delisting of the Company’s common stock from The Nasdaq Capital Market due to the Company’s failure to comply with
the applicable rules, the timing of the hearing and the Panel’s decision, which hearing may be scheduled, and such decision may
be issued, more quickly than expected, the outcome of the hearing and the Panel’s decision, and the other risks set forth in the
Company’s filings with the Securities and Exchange Commission. The forward-looking statements contained in this report speak only
as of the date of this report and the Company undertakes no obligation to publicly update any forward-looking statements to reflect changes
in information, events or circumstances after the date of this report, unless required by law.

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                    IMUNON,